Lexicon Pharmaceuticals
LXRX
LXRX
105 hedge funds and large institutions have $280M invested in Lexicon Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.25% less ownership
Funds ownership: 81.08% → 77.83% (-3.3%)
22% less capital invested
Capital invested by funds: $357M → $280M (-$77.6M)
Holders
105
Holding in Top 10
1
Calls
$296K
Puts
$69K
Top Buyers
| 1 | +$576K | |
| 2 | +$286K | |
| 3 | +$250K | |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$249K |
| 5 |
Fisher Asset Management
Camas,
Washington
|
+$244K |
Top Sellers
| 1 | -$4.83M | |
| 2 | -$539K | |
| 3 | -$224K | |
| 4 |
Natixis Advisors
Boston,
Massachusetts
|
-$212K |
| 5 |
PA
Pinnacle Associates
New York
|
-$209K |